You can't judge based on stock price action in one or two days. You'll see over time. CV therapeutics purchase was thought to be good until GILD's drug in similar space failed. If GILD were really determined to be a leader in HCV, they shouldn't have bought the previous two in oncology and inflammation space.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.